Abstract
Meeting abstracts Glioblastoma multiforme (GBM) is the most common primary malignant human brain tumor and one of the most lethal of all cancer types. Despite the introduction of numerous non-surgical therapies for GBM, clinically relevant responses to treatment are rarely durable. Small
Highlights
Glioblastoma multiforme (GBM) is the most common primary malignant human brain tumor and one of the most lethal of all cancer types
Small populations of stem cells residing within GBM tumors have the ability to differentiate into diverse cell types in vitro and in vivo, and form new heterogeneous tumors in immune compromised mice
We found that primary human GBMs contain a small population of cells (4-14%) expressing high amounts of the stem cell associated protein aldehyde dehydrogenase (ALDH) which can be selectively killed by activated human natural killer (NK) cells
Summary
Bortezomib sensitizes human glioblastoma stem cells to adoptive natural killer cell cytotoxicity. Steven Grossenbacher*, Erik Ames, Stephanie Mac, Yuyou Duan, Syed Azeem, Robert Canter, William Murphy. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
